MetaADEDB 2.0 @ LMMD
fosamprenavir
(PMDQGYMGQKTCSX-HQROKSDRSA-L)
Structure
SMILES
CC(CN(S(=O)(=O)c1ccc(cc1)N)C[C@H]([C@H](Cc1ccccc1)NC(=O)O[C@H]1CCOC1)OP(=O)([O-])[O-])C.[Ca+2]
Molecular Formula:
C25H34CaN3O9PS
Molecular Weight:
623.669
Log P:
5.4491
Hydrogen Bond Acceptor:
12
Hydrogen Bond Donor:
2
TPSA:
201.57
CAS Number(s):
226700-81-8
Synonym(s)
1.
fosamprenavir
2.
(3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-1-(phenylmethyl)-2-(phosphonooxy)propyl)carbamic acid C-(tetrahydro-3-furanyl) ester
3.
GW 433908
4.
GW 433908G
5.
GW 908
6.
GW-433908
7.
GW-433908G
8.
GW-908
9.
GW433908
10.
GW433908G
11.
GW908 cpd
12.
Lexiva
13.
VX 175
14.
VX-175
15.
VX175 cpd
16.
fos-amprenavir
17.
fosamprenavir calcium
External Link(s)
MeSHC426859
PubChem Compound131535
CHEMBLCHEMBL1200734
KEGGdr:D03835
Adverse Drug Event(s)
NameNumber of ReportsReference(s)Data Source
1ConstipationFAERS: 2US FAERS
2NauseaFAERS: 2US FAERS
3Abdominal PainFAERS: 1US FAERS
4Abdominal discomfortFAERS: 1US FAERS
5Abdominal tendernessFAERS: 1US FAERS
6Adverse eventFAERS: 1US FAERS
7AgeusiaFAERS: 1US FAERS
8Alanine Aminotransferase IncreasedFAERS: 1US FAERS
9Angina PectorisFAERS: 1US FAERS
10AnxietyFAERS: 1US FAERS
11Aspartate Aminotransferase IncreasedFAERS: 1US FAERS
12Blood creatine phosphokinase increasedFAERS: 1US FAERS
13Blood lactate dehydrogenase increasedFAERS: 1US FAERS
14Burning sensationFAERS: 1US FAERS
15Cerebrovascular accidentFAERS: 1US FAERS
16Disease recurrenceFAERS: 1US FAERS
17Drug dispensing errorFAERS: 1US FAERS
18Drug dose omissionFAERS: 1US FAERS
19Drug ineffectiveFAERS: 1US FAERS
20Erectile dysfunctionFAERS: 1US FAERS
21Facial wastingFAERS: 1US FAERS
22FlatulenceFAERS: 1US FAERS
23HeadacheFAERS: 1US FAERS
24HypersensitivityFAERS: 1US FAERS
25ImmobileFAERS: 1US FAERS
26InfluenzaFAERS: 1US FAERS
27Lip and/or oral cavity cancerFAERS: 1US FAERS
28MalaiseFAERS: 1US FAERS
29Muscle CrampFAERS: 1US FAERS
30MyalgiaFAERS: 1US FAERS
31MyopathyFAERS: 1US FAERS
32NasopharyngitisFAERS: 1US FAERS
33Product dose omissionFAERS: 1US FAERS
34Product residue presentFAERS: 1US FAERS
35Product substitution issueFAERS: 1US FAERS
36PruritusFAERS: 1US FAERS
37Stevens-Johnson SyndromeFAERS: 1US FAERS
38Terminal stateFAERS: 1US FAERS
39Therapy cessationFAERS: 1US FAERS
40Therapy changeFAERS: 1US FAERS
41ThrombocytopeniaFAERS: 1US FAERS
42VomitingFAERS: 1US FAERS
Powered by :

Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120239

Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.